Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: Possible role for chemotherapeutic intervention

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 9, 2007, Pages 1350-1360

  Achcar, Rosane De Oliveira Duarte ^a   Cagle, Philip T ^b   Jagirdar, Jaishree ^a,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; GENE INACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; METASTASIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMOKING; TUMOR CELL; UPREGULATION; APOPTOSIS; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG TUMOR; MESOTHELIOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LUNG; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; STAT3 TRANSCRIPTION FACTOR;

EID: 34548710844     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-2488.
2. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002;2:740-749.
3. Darnell JE Jr. STAT gene regulation. Science. 1977;277:1630-1635.
4. Bromberg J. Stat 3 protein and oncogenesis. J Clin Invest. 2002;109:1139-1142.
5. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer. 2004;4:97-105.
6. Chen CL, Hsieh FC, Lieblein JC, et al. Stat3 activation in human endometrial and cervical cancers. Br J Cancer. 2007;96:591-599.
7. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation [published online ahead of print November 28, 2006]. Cancer Lett. doi:10.1016/j.canlet.2006.10.017.
8. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE. 2006;343:pe30.
9. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer associated mutations of the epidermal growth factor receptor. Cancer Res. 2006;66:3162-3168.
10. Song L, Turkson J, Karras JG, Jove R, Haura B. Activation of Stat 3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinomas cells. Oncogene. 2003;22:4150-4165.
11. Ng DC, Lin BH, Lim CP, et al. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol. 2006;172:245-257.
12. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimmers and increases the catastrophe rate of microtubules. Cell. 1996;84:623-631.
13. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 2004;64:3550-3558.
14. Haura BE, Zheng Z, Song L, Cantor A, Bebler G. Activated epidermal growth factor receptor - Stat-3 signaling promotes tumor survival in vivo in non small cell lung cancer. Clin Cancer Res. 2005;11:8288-8294.
15. Sanchez-Ceja SG, Maldonado ER, Gutierrez-Castellanos S. Differential expression of STAT 5 and Bcl-xl, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer. 2006;54:163-168.
16. Song L, Turkson J, Karras JG, Jove R, Haura B. Activation of Stat 3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinomas cells. Oncogene. 2003;22:4150-4165.
17. Song H, Wang R, Wang S, Lin J. A low molecular weight compound discovered through virtual database screening inhibits Stat 3 function in breast cancer cells. Proc Natl Acad Sci U S A. 2005;102:4700-4705.
18. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets. 2004;8:409-422.
19. Sun J, Blaskovich MA, Cucurbitacin Q. A selective STAT 3 activation inhibitor with potent antitumor activity. Oncogene. 2005;24:3236-3245.
20. Leong PL, Andrews GA, Grandis GR. Targeted inhibition of Stat 3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003;100:4138-4143.
21. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000;19:6613-6626.
22. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11:623-629.
23. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy D. New and old function of Stat 3. Cell Cycle. 2005;4:1131-1133.